Kura Oncology
KURA
140 hedge funds and large institutions have $1.15B invested in Kura Oncology in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 44 reducing their positions, and 15 closing their positions.
133% more call options, than puts
Call options by funds: $987K | Put options by funds: $424K
68% more capital invested
Capital invested by funds: $687M → $1.15B (+$465M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
6.37% more ownership
Funds ownership: 101.46% → 107.83% (+6.4%)
5% more funds holding
Funds holding: 133 → 140 (+7)
9% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$24.6M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$16.4M |
| 3 |
DM
Deerfield Management
New York
|
+$9.23M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$6.32M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$9.66M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$6.54M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.22M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$3.83M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.46M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$4K | -413 | Closed |
|
152
Allspring Global Investments
Charlotte,
North Carolina
| – | -$3.19K | -350 | Closed |
|
|
NA
153
NewEdge Advisors
New Orleans,
Louisiana
| – | -$1.96K | -215 | Closed |
|
|
GWS
154
Glassman Wealth Services
Vienna,
Virginia
| – | -$1.67K | -183 | Closed |
|
|
C
155
Covestor
London,
United Kingdom
| – | -$10 | -1 | -9% |
|
KURA Hedge Fund Activity: Q4 2023 in Review
140 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q4 2023, worth a combined $1.15B — up 68% from $687M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new KURA positions and 15 closed out — a net gain of 7 holders — while 48 added to existing stakes and 44 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $24.6M. The largest seller was Prosight Management, cutting an estimated $9.66M.
- 140 institutional investors held Kura Oncology (KURA) as of Q4 2023, up from 133 in Q3 2023.
- Funds reported $1.15B of Kura Oncology stock for Q4 2023, up 68% quarter-over-quarter.
- 22 funds opened new Kura Oncology positions in Q4 2023 and 15 closed out, a net change of +7 holders.
- The largest Kura Oncology buyer in Q4 2023 was Morgan Stanley, an estimated $24.6M added.
- The largest Kura Oncology seller in Q4 2023 was Prosight Management, an estimated $9.66M sold.
Based on aggregated 13F filings for Q4 2023.